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People with a learning disability are often disadvantaged due to the nature of their disability. Up to a third are likely to have 
concomitant epilepsy which adds to the health loss experienced by this group. It is important to manage their epjlepsy in such a 
way as to limit the debilitating effects of both the illness and the medication. Rectal diazepam remains the gold standard rescue 
medication for prolonged, recurrent seizures or seizures associated with hypoxia. Some of the drawbacks are highlighted in this 
paper and we go on to explore a novel means of treating these seizures. Midazolam, via the intranasal route, has been used 
extensively in children, mostly as a sedative but also in the treatment of epilepsy. We present two cases, both are adults with a 
learning disability, who have benefited significantly from the use of intranasal midazolam. Ongoing research into the safe use 
of this form of treatment, training of staff and carers and the impact on the individual is being conducted. 
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INTRODUCTION 
A learning disability is a clinical entity defined by 
statistics. The population with a learning disability is 
very heterogeneous, but the precise definition of an 
individual with a learning disability (according to the 
American Diagnostic and Statistical Manual for Psy- 
chiatric Disorder) is a person who has an IQ of less 
than 70 and whose ability to adapt and survive within 
society is limited’. 
In addition to their learning disability, 15-30% will 
have epilepsy. In general, the more severe the degree 
of learning disability the more likely the possibility of 
epilepsy occurring and, in addition, their seizures are 
often of a severe and complex nature*. The diagnosis 
and management of their epilepsy is complicated by 
problems with communication, difficulties with coop- 
eration for investigations and a general failure on the 
part of carers and health professionals alike to recog- 
nise the more subtle forms of seizure3. 
Epilepsy is a significant cause of health loss in the 
learning disabled population and it is of concern that 
some are not able to access the local facilities because 
of the chance that they might have a prolonged seizure 
and require medication whilst out. 
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A seizure is considered to be prolonged if it lasts 
longer than 5 minutes or if there are two or more con- 
secutive seizures of shorter duration without a return to 
consciousness between these seizures. Some patients 
may have a cluster of seizures following the initial 
seizure whilst others may have hypoxic episodes dur- 
ing the tonic phase leading to cyanosis. 
MATERIALS AND METHODS 
Current practice 
Rectal diazepam is the current gold standard for the 
treatment of prolonged seizures and although an effec- 
tive treatment for many patients it does have drawbacks. 
The variable nature of the absorption of the drug when 
administered rectally, carers’ attitudes to rectal admin- 
istration and the embarrassment o the patient com- 
pound difficulties with its use. Furthermore, the long 
half-life (20-40 hours) can lead to prolonged sedation 
as an unwanted side effect”. This drowsiness may have 
the paradoxical effect of lowering the seizure threshold 
making the patient more susceptible to further seizures. 
Other problems with this treatment are fairly com- 
mon as reported by both carers and patients. Fear of 
rectal Diazepam administration has been cited as a rea- 
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son for truancy among older children with epilepsy, 
embarrassment following the administration of a rectal 
drug is described, some carers feel that this is a form 
of sexual abuse and it is an unacceptable treatment to 
administer in a public place3. 
Many local authority carers refuse to administer rec- 
tal medication, schoolteachers are reluctant to use this 
form of treatment unless supervised, whilst other carers 
have difficulty administering this medication despite 
adequate training6. 
With the resettlement of people with a learning dis- 
ability back into the community it has become essential 
to look for other methods of emergency treatment and 
alternative routes of administration which would allow 
the individual to access the community with as little 
restriction as is possible3. 
Diazepam was one of the earliest benzodiazepines 
first used in 1962. It is highly lipid soluble and so 
diffuses rapidly into the central nervous system but 
equally its high lipid solubility means that it is stored 
in body fat so that it has a high volume of distribu- 
tion affecting its elimination’. It has been used both 
intravenously and rectally*. Intramuscular absorption 
has been too variable and has not been recommended 
for treatment of seizures3. Both midazolam and clon- 
azepam have been used intravenously, intramuscularly 
and orally for the short term management of seizures3. 
Alternative practice 
Easily accessible options for the delivery of drugs in 
the acute situation are the nasopharangeal and the sub- 
lingual mucosal surfaces ‘s9. Midazolam via this route 
is widely used in anaesthetic practice*, lo, 1 t , particu- 
larly in children 12-t5. This has prompted the use of 
intranasal and sublingual midazolam in the treatment 
of seizure disorders in childret& *&t8. 
There would appear to be further value in its use 
as a sedative agent in people with a learning dis- 
ability who are undergoing procedures’9*20 as it can 
be safely administered via the intranasal or sub- 
lingual routes 13. There have been numerous stud- 
ies confirming its efficacy and comparing the differ- 
ences between intravenous, intranasal or intramuscular 
adfinis&ation’ov II*15**1.**. 
Midazolam is a water-soluble, short-acting, benzo- 
diazepine introduced into clinical practice in 1982. It is 
commonly used in anaesthetic practice where its value 
as a pre-medication is well documented. It is rapidly ab- 
sorbed from oral, intramuscular and intravenous routes 
with significant anxiolytic, sedative and anterograde 
amnesic effects5. 
The pharmacology and pharmacokinetics are well 
known. It is an imidazobenzodiazepine with an open 
structure maintained whilst in an acidic suspension. At 
physiological pH the ring structure closes and the drug 
becomes lipid soluble and therefore is able to readily 
cross the blood-brain barrier’*. Midazolam is princi- 
pally cleared by hepatic enzymes with a mean elimi- 
nation half-life of 2 hours in healthy subjects’. It can 
be administered as a bolus and does not cause signif- 
icant haemodynamic or respiratory changes at a dose 
of 0.2 mg/kg”*‘2*20~23. 
The pharmacological properties of midazolam are 
typical of the benzodiazepine class, namely: hypnotic, 
anxiolytic, muscle relaxant and anticonvulsant effects. 
The anticonvulsant action is thought to be due to its en- 
hancement of y-aminobutyric acid (GABA) which as 
the main inhibitory neurotransmitter in the brain causes 
hyperpolarisation of the cells reducing their chance of 
firing. 
In view of this alternative route of administration for 
a drug with recognised efficacy in status epilepsy, it has 
been tried on a number of adults with a learning dis- 
ability who would normally have required large doses 
of diazepam administered rectally. Two cases are de- 
scribed as follows. 
Case 1 
A 25year-old female with idiopathic generalised 
epilepsy and a moderate learning disability was admit- 
ted to a specialist epilepsy centre for assessment of her 
seizure disorder. Seizures included absences and tonic- 
clonic events, the latter lasting up to 1 hour without 
emergency intervention. They were also characterised 
by marked central cyanosis, necessitating administra- 
tion of oxygen. Prior to admission, the frequency of 
tonic-clonic events was between two and six per day 
with rectal diazepam being given on each occasion, fol- 
lowed by post-ictal sleep lasting anything up to 5 hours. 
The situation was further complicated by a local social 
services policy which prevented administration of rec- 
tal medication by carers at the day centre attended by 
the patient. As a consequence, the patient’s father was 
contacted at his nearby workplace on a daily basis, so 
that he could administer the diazepam. 
On admission the patient was lethargic, sedated and 
in a wheelchair. She was taking optimal doses of lam- 
otrigine and controlled release sodium valproate which 
were not altered, but rectal diazepam was replaced by 
intranasal midazolam for the management of prolonged 
seizures. 
Within 2 weeks of commencing intranasal rnidazo- 
lam and concomitant cessation of rectal diazepam, she 
was alert, bright, no longer required a wheelchair and 
was even playing football. By using midazolam, tonic- 
clonic seizures were aborted within 2-5 minutes and 
a full and uneventful recovery effected within 10-20 
minutes, allowing her to continue her daily activities. 
The improvement has continued following her dis- 
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charge, with staff at the day centre administering the 
midazolam intranasally. It is interesting to note that 
she only required midazolam on two to three occasions 
per week as opposed to up to six times daily for rectal 
diazepam. 
Case 2 
A 20-year-old male student with a moderate to se- 
vere learning disability was attending a college for 
further education. He had experienced complex par- 
tial and tonic-clonic seizures since childhood. The lat- 
ter were prolonged and he frequently became centrally 
cyanosed, requiring oxygen. He was taking a combina- 
tion of lamotrigine, controlled release sodium valproate 
and topiramate, but still experienced at least one severe 
tonic-clonic seizure per week. He required 30 mg of 
rectal diazepam and occasionally rectal paraldehyde 
for the control of prolonged seizures; frequently sleep- 
ing for up to 4 hours following these events and rescue 
drug administration. 
A major precipitant of tonic-clonic events appeared 
to be excitement and, as a consequence, college ex- 
cursions and community placements were frequently 
hindered leading to the eventual denial of access to 
social experiences. 
Intranasal midazolam, in this patient, took effect 
within 3-4 minutes; a full recovery ensuing within lO- 
15 minutes. 
DISCUSSION 
There have been a number of studies comparing doses 
and serum concentrations of midazolam and the con- 
clusion has been that a dose of intranasal midazolam 
of 0.2 mg/kg, as for the intravenous route, is the opti- 
mum dose in children. Separate studies have confirmed 
that in most patients, within 10 minutes of receiving 
this dose, sedation is induced when the drug is being 
used in anaesthetic practice’***’ and EEG monitored 
seizure& l6 are terminated when it is being used to 
treat epilepsy. 
Local effects such as sneezing and coughing are dose 
related and occur less frequently at 0.2 mg/kgZ3. Pa- 
tients administered this drug intranasally whilst awake 
have noted discomfort or an odd sensation at the back 
of their throats but all who could compare between 
intranasal, intravenous or rectal routes of administra- 
tion preferred the intranasal route5. The only condition 
associated with failure is the presence of an upper res- 
piratory tract infection with copious nasal secretions. 
A comparative study of the plasma concentration of 
intravenous, intranasal and rectal administered mida- 
zolam of 0.2 mg/kg has shown that both intravenous 
and intranasal routes avoid first pass metabolism and 
achieve similar concentrations at 45 minutes, whereas 
rectal administration leads to a significantly lower peak 
plasma concentration’O. 
Because medically untrained carers are usually ex- 
pected to administer the drug, a simple and safe method 
needs to be employed. At present the preparation used 
is the intravenous midazolam, 10 mg in 2 ml, solution. 
The equipment required for administration is a 2.5 ml 
syringe and a neonatal nasogastric feeding tube. The 
administration of the drug is via the intranasal route so 
an accumulation of air in the system is not a problem. 
In our experience it is not appropriate to determine the 
dose per kilogram in adults although we do advise that 
patients below 50 kg receive a dose of 5 mg whilst for 
those over 50 kg a dose of 10 mg is used. 
CONCLUSION 
In both cases described, the patients’ parents were 
trained in the use of intranasal midazolam and were able 
to administer it with good effect. Non-professional care 
staff were also trained in its use and were comfortable 
with its administration. The rapid recovery rate facili- 
tated by using midazolam as an alternative to diazepam 
obviously had significant implications for both patients 
in the cases described, affecting their education, social 
development and quality of life. 
Initial evaluation of intranasal midazolam seems to 
show that it has significant advantages over rectal di- 
azepam. Midazolam has a much shorter half-life and 
a smaller volume of distribution than diazepam and 
so does not accumulate in the body. Due to these dif- 
ferences the recovery time following administration is 
shorter. The route of administration is also significantly 
more acceptable to both patients and carers providing a 
more dignified method of rescue medication delivery. 
Further refinement of the drug and the delivery sys- 
tem are required to make this a universally acceptable 
practice. Midazolam is currently licensed as an anaes- 
thetic agent with known anticonvulsant effects; it is, 
however, unlicensed for the intranasal route. 
No local effects have been noted in the individuals 
treated thus far, but the low pH of midazolam could 
potentially damage the mucosal surface if used repeat- 
edly over several hours. The current volume of l-2 ml 
does not cause any problems but might be better ab- 
sorbed if delivered in a nasal spray which would also 
decrease the required dose. A nasal spray would also 
reduce the risk of injury to medically untrained staff 
who sometimes find breaking the glass vial a difficult 
task. One requirement before this treatment can even 
be considered is that nursing staff and carers must be 
trained in the technique so that the delivery is both safe 
and effective. 
As an alternative emergency treatment to rectal di- 
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azepam, this drug and administration route appears to 
provide great promise. Prospective trials comparing the 
efficacy of intranasal midazolam with rectal diazepam 
have commenced and we anticipate this new emergency 
treatment could provide significant benefits for an al- 
ready disadvantaged group of patients. 
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